The short version
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Biktarvy
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate · BICTEGRAVIR SODIUM 50 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE FUMARATE 25 mg/1 · Tablet · Oral · A-S Medication Solutions
NDC 50090-6247-00 · 30 TABLET in 1 BOTTLE, PLASTIC · NDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 61958-2501-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$136.05per unit
middle half $133.66–$140.89 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
$81.63–$102.04
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
100%of plans cover it
tier 5 · prior auth 0% · step therapy 0% · qty limit 57%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- A-S Medication Solutions LLCUnited Statesrelabel
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $4,110.58 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA210251
- TE code
- —
- Approval date
- Feb 7, 2018
- Patents / exclusivity
- 20 patents, 9 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | ODE-540 | Jul 30, 2032 |
| exclusivity | ODE-540 | Jul 30, 2032 |
| exclusivity | ODE-468 | Feb 23, 2031 |
| exclusivity | ODE-468 | Feb 23, 2031 |
| exclusivity | ODE-378 | Oct 7, 2028 |
| exclusivity | M-305 | Apr 24, 2027 |
| exclusivity | I-942 | Feb 23, 2027 |
| exclusivity | I-942 | Feb 23, 2027 |
| exclusivity | ODE-256 | Jun 18, 2026 |
| patent | 11744802 | Nov 8, 2036 |
| patent | 12594244 | Nov 8, 2036 |
| patent | 10548846 | Nov 8, 2036 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | BICTEGRAVIR SODIUM 50 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE FUMARATE 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Gilead Sciences, Inc. | BICTEGRAVIR SODIUM 50 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE FUMARATE 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Patheon Inc. | BICTEGRAVIR SODIUM 50 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE FUMARATE 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Rottendorf Pharma GmbH | BICTEGRAVIR SODIUM 50 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE FUMARATE 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Takeda GmbH | BICTEGRAVIR SODIUM 50 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE FUMARATE 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Gilead Sciences, Inc. | BICTEGRAVIR SODIUM 30 mg/1; EMTRICITABINE 120 mg/1; TENOFOVIR ALAFENAMIDE FUMARATE 15 mg/1 | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Biktarvy — NDC 50090-6247-00," retrieved September 3, 2026, https://drugdashboards.com/drug/50090624700.
Free to cite with attribution — see how the data is put together.